Mosh (Australia)
Mosh (Australia) scored 60/100 on Panya's 11-signal vendor rubric. Each signal is scored 0 to 100, the methodology is public, and our affiliate posture is flat-fee · never pay-to-rank. Below is the full per-signal breakdown.
- COA on every lot75
- Cold-chain verified70
- Rx legalityTGA-licensed; AHPRA-registered prescribers. Smaller compliance footprint than the Eucalyptus brands but operating under the same Sept 2025 TGA advertising rules70
- Compound identity75
- Dose accuracy75
- Endotoxin testing70
- Refund posture60
- Channel claritySubscription model with multiple men's-health surfaces (hair, ED, weight)60
- Support quality65
- Price transparency65
- Longitudinal retentionSmaller scale than Eucalyptus brands; sustained operation through 2024-26 GLP-1 demand wave55
TGA-approved for T2D, off-label weight prescribing legal. Juniper / Eucalyptus / Hub Health all stocking; no reported gaps.
Recovered from the severe 2023-24 shortage that prioritised T2D patients over weight-only access.
August 2024 launch eased the pressure, but Wegovy supply remains tighter than tirzepatide.
The 11-signal rubric is public.
Identity, dose accuracy, COA, cold-chain, Rx legality, compound identity, endotoxin testing, refund posture, channel clarity, support quality, price transparency, longitudinal retention. Each scored 0 to 100. Vendors that fail our floor are silently filtered out · they don't appear in our match flow at all.
If Mosh (Australia) wants to dispute or update this score, contact partner@panya.health. Score updates are recorded on this page with a public changelog.
Want a match for your situation?
Take the 2-minute quiz. We'll match you against this and the other vendors in your region · based on your dose, urgency, and budget.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.